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progressive lactotroph hyperplasia and a secondary le-
sion in the reproductive tract identified as uterine adeno-
myosis. Surprisingly, the size of the IL did not correlate
with D2 receptor genotype. Although there were no ap-
parent consequences of the loss of D2 receptor tone
on melanotroph number, the storage of a-melanocyte
stimulating hormone (a-MSH) in the IL was significantly
reduced in the mutant mice. Therefore, the chronic loss
of dopaminergic inhibitory tone to the pituitary gland
resulted in a complex endocrine phenotype, revealing
a physiological role for dopamine in regulating the cell
number of lactotrophs.
Results
Disruption of the D2 Receptor Gene
A 12 kb genomic clone containing exons 6, 7, and 8 of
the D2 receptor was isolated from a 129/SvEv phage
library, using a rat D2 receptor cDNA hybridization probe
(Bunzow et al., 1988). Using standard subcloning tech-
niques, all of exon 7 and the 59 half of exon 8 were
deleted and replaced by a neomycin resistance cassette
(Figure 1A). Any transcripts from the targeted gene
should lack sequence encoding the majority of the puta-
tive third intracellular loop throughthe carboxyterminus.
Homologous recombinants were detected by Southern
blotting, using a 59 flanking probe, followed by confirma-
tion of the39 flanking structure with a second probe (data
not shown). One of four clones injected into C57BL/
6J (B6) e3.5 blastocysts generated multiple male and
female chimeras. Five male chimeras were bred to B6
females, and all produced heterozygous offspring. The
F1 heterozygous mice of this mixed 129 3 B6 back-
ground were interbred and produced F2 offspring of all
three possible genotypes (Figure 1B).Northern blot anal-
ysis of the F2 generation (Figures 1C and 1D) revealed
that 1/2 mice have approximately 50% (by banddensity
comparison) of the D2 mRNA compared with their 1/1
siblings; 2/2 mice demonstrated a faint band of smaller
size, consistent with the predicted truncated transcript
from the mutated allele. Figure 1. Generation of D2 Receptor-Deficient Mice
D2 receptor density was analyzed by membrane bind- (A) Homologous recombination. The endogenous mouse D2 dopa-
ing assays as previously described (Bunzow et al., 1995; mine receptor locus, targeting vector with neo cassette, and pre-
dicted D2 allele after homologous recombination are depicted. AZhang et al., 1996) with an antagonist radioligand (See-
portion of the genomic clone that lies 59 to the targeted sequenceman et al., 1994), using striata from adult 2/2, 1/2,
was retained for use as a probe (probe A) for genotyping. RV, EcoRand 1/1 mice (Figure 1E). Specific [3H]-nemonapride
V; A, Apa1; S, Sac 1.
(specific activity 82 Ci/mmol, DuPont New England Nu- (B) Southern blot analysis of genomic DNA. Digestion of genomic
clear) binding was absent in D22/2 mice. Nonspecific DNA with the restriction enzyme EcoR V results in a 9.5 kb band
binding was defined in thepresence of 1 mM (1) butacla- for recombinants and a 3.8 kb band for wild-type mice when hybrid-
ized to probe A. All three genotypes are shown.mol (Bunzow et al., 1988). Bmax values were significantly
(C) Northern blot analysis of mRNA transcripts. Mouse forebraindifferent (one-way ANOVA, p , 0.001 by Tukey post hoc
mRNA was blotted and probed for D2 receptor transcripts using aanalysis) for the 1/1 (289 6 9 fmol/mg protein), 1/2
0.77 kb cDNA fragment corresponding to a portion of the mouse
(145 6 8 fmol/mg protein), and 2/2 (0 fmol/mg protein) D2 receptor. Indicated are the ribosomal bands (18S and 28S) as
mice when compared between genotypes. In contrast, well as the expected message length of the wild-type transcript
Kd values for the 1/1 (41 6 9 pM) and 1/2 (36 6 7 pM) (2.5 kb).
(D) Normalization of Northern blot loading. The same blot shown inmice were the same.
panel (C) was reprobed with a mouse cyclophilin cDNA probe.The growth and development of F2 mice were indistin-
(E) Dopamine D2 receptor membrane binding. Saturation bindingguishable based on D2 receptor genotype, and adult
of [3H] nemonapride to mouse striatal membranes is shown. TheD22/2 mice attained body weights equivalent to their inset is a Scatchard transformation of the data. The curves are
sibling controls, despite a deficit in spontaneous loco- representative of saturation isotherms conducted in triplicate using
motion (unpublished data). Dopamine D2 receptor-defi- membranes prepared from two animals per group. Similar results
were obtained with repeated experiments (n 5 3).cient mice developed structurally normal pituitary glands
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and progressed through puberty. In contrast to a previ- Anterior Pituitary Hyperplasia in D2
Receptor-Deficient Miceous report (Baik et al., 1995), pure homozygous litters
were reared successfully from matings between pairs Six- to twelve-week-old mice of all genotypes, regard-
less of sex or genetic background, had no discernibleof F22/2 mice. It is possible that this difference in fecun-
dity is related to the specific substrain of 129 mice used differences in pituitary size or appearance. However, by
nine (congenic N5) or twelve (F2) months of age everyto generate the ES cells used in the respective experi-
ments. Testosterone and estradiol levels of sexually ma- D22/2 female examined (n 5 24) had developed anterior
lobe hyperplasia, with pituitary weights ranging fromture 8-week-old mice were not different between sibling
groups (data not shown). Mice of all genotypes and ages 4±10-fold greater than normal. This distinctive hyperpla-
sia was never observed in age-matched D21/2, wild-appeared healthy, with shiny coats, good muscle tone,
and alert behavior. Notwithstanding these impressions type 129, or wild-type B6 females (n 5 32), nor in any
male of any genotype. On gross observation, the olderof overall good health and no differences in perinatal
loss among the genotypes, there was a small, unex- D22/2 females had diffusely enlarged, hyperemic ante-
rior pituitary lobes without focal nodules.plained skewing of the expected Mendelian genotype
ratio of 2/2 mice to about 1:5 instead of 1:4 from a Microscopic examination of the enlarged pituitaries
revealed hyperplasia and hypertrophy of the anteriorbreeding colony of 1/2 mice.
lobes, with prominent vascular spaces (Figures 3A and
3B). Although the glandular acini were enlarged, theHypersecretion of Pituitary Prolactin in D2
Receptor-Deficient Mice Gordon-Sweet stain demonstrated an intact reticulin
network throughout the anterior pituitary (Figures 3CD22/2 mice had basal serum prolactin levels 3-fold
higher than their wild-type siblings of the same sex on and 3D). Immunohistochemistry documented the pres-
ence of all of the adenohypophysial hormones, but theboth the F2 129 3 B6 (data not shown) and the congenic
B6 background by 6 weeks of age (Figure 2A). The con- D22/2 mice had a markedly increased number of cells
containing prolactin (Figures 3E and 3F). Confocal mi-stitutively high serum prolactin levels were not elevated
further when D22/2 mice were treated with 5 mg/kg of croscopic examination of immunofluorescent antibody
labeled lactotrophs further demonstrated a predominantthe D2 receptor antagonist haloperidol (Figures 2B and
2C). In contrast, both male and female siblings (1/2 juxtanuclear localization of immunoreactive prolactin on
the D22/2 pituitaries, in contrast to the staining patternand 1/1) demonstrated significant increases in serum
prolactin in response to haloperidol. When analyzed by of cytoplasmic processes containing secretory granules
on 1/1 mice (Figures3G and 3H). The different subcellu-sex, prolactin values in females were all higher than
in males (one way ANOVA, p , 0.0001), regardless of lar localization of prolactin in the D22/2 mice is charac-
teristic of hyperstimulated lactotrophs with rapid turn-genotype, because of the known actions of estrogen to
induce prolactin gene expression and storage in secre- over of prolactin and limited storage capacity. There
was a relative decrease in the number of cellscontainingtory granules (Kiino and Dannies, 1981). Serum prolactin
levels were measured in a small number of aged D22/2 other hormones but the size, shape, and overall distribu-
tion in the gland of somatotrophs, corticotrophs, andmice and increased dramatically to 1670 6 427 ng/ml
(n 5 4) in females, while male values remained stable thyrotrophs was similar in D22/2 mice compared with
aged controls. However, there was a more pronouncedover time.
Figure 2. Serum Prolactin
(A) Basal serum prolactin levels were elevated in D22/2 mice. Prolactin levels were analyzed by RIA on serum from stress-free, drug-naive
animals. D22/2 mice of both sexes have significantly higher prolactin levels. Shown are mean values 6 SEM. Female 2/2, n 5 7; female 1/2,
n 5 13; female 1/1, n 5 15; male 2/2, n 5 7; male 1/2, n 5 18; male 1/1, n 5 14. *, p , 0.0001 compared with 1/2 or 1/1 mice.
(B) and (C) A D2 receptor antagonist had no effect on serum prolactin in D22/2 mice. Prolactin levels were analyzed by RIA on serum from
female (B) and male (C) mice treated sequentially with saline to control for the stress of handling and injection (solid bars), then with haloperidol
(5 mg/kg BW; striped bars). D22/2 mice did not increase serum prolactin levels in response to haloperidol, while both 1/2 and 1/1 levels
increased significantly.
(B) Note that the female 1/2 and 1/1 mice had sufficient stored prolactin to acutely increase serum levels well above the constitutively
elevated levels of the 2/2 females. Female 2/2, n 5 6; female 1/2, n 5 16; female 1/1, n 5 6.
(C) Male 1/2 and 1/1 animals had increased prolactin levels in response to haloperidol; but note that, unlike females of the same genotype,
they did not surpass the basal 2/2 levels. Male 2/2, n 5 7; male 1/2, n 5 14; male 1/1, n 5 7. Note the different Y axis scales among the
panels. *, p , 0.0001 within subjects; **, p , 0.0001 compared with 2/2 mice.
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Figure 3. Anterior Pituitary Hyperplasia Found in Aged D2 Receptor-Deficient Females
(A±J) Comparisons between the pituitaries of aged D22/2 female mice with D21/1 mice on the F2 129 3 B6 background.
(A) The pituitary of a control mouse has a nesting architecture with fibrovascular stroma.
(B) The pituitary of a D22/2 mouse is composed of large nests of adenohypophysial cells with abundant chromophobic cytoplasm; dilated
blood-filled spaces are prominent (arrow).
(C) The Gordon-Sweet silver stain of a control mouse reveals the normal acinar architecture of the adenohypophysis.
(D) The Gordon-Sweet silver stain confirms the presence of an intact reticulin fiber network in the pituitary of a D22/2 mouse; while the
parenchyma has preserved acinar architecture, individual acini are larger (arrow) than controls.
(E) Immunohistochemistry of the anterior pituitary in a control mouse demonstrates the presence of prolactin immunoreactivity in many cells.
(F) In the D22/2 mouse, there is a marked increase in the percentage of adenohypophysial cells staining positively for prolactin.
(G) Immunofluoresence of the anterior pituitary examined by confocal microscopy demonstrates both juxtanuclear and cytoplasmic (large
green fluorescent areas) prolactin immunoreactivity. The nuclei are stained blue with Hoechst dye when examined under ultraviolet light.
(H) The prolactin immunoreactivity is almost completely juxtanuclear (small focal areas of green immunofluoresence) in the D22/2 pituitary.
(I) Immunohistochemistry of the anterior pituitary in a control mouse demonstrates abundant immunoreactive gonadotrophs.
(J) In the D22/2 mouse, there is a marked reduction in the number of immunoreactive gonadotrophs.
Scale bars, 50 mm (A±F, I, J); 3 mm (G, H).
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Figure 4. Electron Microscopy of Lactotroph
Hyperplasia and Peliosis in the Anterior Pitu-
itary of D2 Receptor-Deficient Mice
(A) The anterior pituitary of the D22/2 mouse
is composed primarily of lactotrophs. By
electron microscopy, the anterior pituitary of
a D22/2 mouse is composed mainly of hyper-
trophic, active lactotrophs with well-devel-
oped rough endoplasmic reticulum, large
Golgi complexes, and few pleomorphic se-
cretory granules that exhibit misplaced exo-
cytosis, i.e. extrusion along the lateral cell
border (arrow). Scattered other cells are inter-
spersed, such as the somatotroph with nu-
merous large, electron-dense granules seen
at the top (arrowhead).
(B) The anterior pituitary exhibits peliosis,
large blood-filled spaces that lack endothelial
lining (arrow). The cells surrounding these
cavities are hyperplastic lactotrophs; there is
no evident necrosis or inflammation to ac-
count for the extravasation of erythrocytes.
Original magnification, 67003.
reduction in gonadotrophs immunoreactive for b-follicle separate from dilated but usually empty capillaries.
stimulating hormone (b-FSH) and b-luteinizing hormone There was no associated necrosis, inflammation, or fi-
(b-LH; Figures 3I and 3J). Together, these features are brosis. The cells surrounding these peliotic cavities were
consistent with lactotroph hyperplasia, with no sugges- adenohypophysial cells with prominent lactotrophs, not
tion of adenomatous transformation as evidenced by different from those in the remainder of the parenchyma.
reticulin breakdown or preferential cell distribution in We measured the cAMP content of anterior pituitaries
any pituitary examined (n 5 9). to determine if the chronic loss of D2 receptor signaling
Electron microscopy revealed the enlarged pituitaries through inhibition of adenylyl cyclase might cause the
of female D22/2 mice to have a marked prominence of observed pathological effects. Paradoxically, the cAMP
stimulated lactotrophs (Figure 4A). Other pituitary cell content in both 2/2 and 1/2 females was significantly
types were interspersed throughout the gland and main- decreased compared to wild-type siblings (Figure 5),
tained their normal appearance. The hyperplastic lacto- strongly suggesting that the lactotroph hyperplasia is
trophs had well-developed rough endoplasmic reticulum cAMP independent. Male mice, which do not develop
profiles that formed large prominent Golgi complexes hyperplasia, had no differences in anterior lobe cAMP
termed Nebenkerns. There were a few pleomorphic se- content across genotypes.
cretory granules, usually in the Golgi region. Occasional
granules exhibited misplaced exocytosis. Vascular
Adenomyosis in Aged Female D2channels were prominent in all of the D22/2 mice, and
Receptor-Deficient Micethe anterior lobes of several mice exhibited extravasated
In 9 out of 16 one-year-old F2 female D22/2 mice, wered blood cells or peliosis (Figure 4B). Peliosis is charac-
noted the appearance of obviously abnormal uteri notterized by blood-filled cavities that lack endothelial lin-
ings, are not surrounded by reticulin fibers, and are present incomparably aged wild-type mice of any strain.
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normal and contained corpora lutea indicative of ovu-
lation.
Absence of Intermediate Lobe Hyperplasia
The 129 parental strain possesses a demonstrably larger
intermediate lobe than the B6 strain, resulting in extreme
variability in the F2 offspring, which was independent of
D2 receptor status (Figure 7). Morphometric analysis
revealed an IL thickness of 240 6 80 mm in 129 mice
compared to 110 6 30 mm in B6 mice. The F2 D2 2/2
mice had an IL thickness of 210 6 50 mm. No differences
of IL size between D22/2, D21/2, and D21/1 mice were
observed even on the N5 congenic B6 background (data
not shown).
Figure 5. cAMP Levels Were Not Elevated in the Anterior Pituitary a-MSH content of the neurointermediate lobe was
of D22/2 Mice significantly decreased in male F2 and N52/2 mice when
Pituitary anterior lobes from six-week-old mice were analyzed by compared with siblings, while 1/2 mice had signifi-
RIA for cAMP. In contrast to the expected result, cAMP levels were cantly higher a-MSH neurointermediate lobe content
not increased by the permanent loss, in vivo, of the D2 receptor.
than any other genotype (2/2, 70 6 9 pmol a-MSH/IL;Female D22/2 and 1/2 mice are significantly lower than D21/1
1/2, 213 6 19 pmol a-MSH/IL; 1/1, 148 6 14 pmolfemales. Shown are mean values 6 SEM. Female 2/2, n 5 7;
female 1/2, n 5 13; female 1/1, n 5 14; male 2/2, n 5 7; a-MSH/IL; one-way ANOVA, p , 0.04), indicating an
male 1/2, n 5 15; male 1/1, n 5 12. *, p , 0.0001 compared with effect of D2 receptor number on storage of POMC pep-
female 2/2 and 1/2 groups. tides in melanotrophs, analogous to the situation of pro-
lactin in lactotrophs. The continuous release of bioactive
a-MSH by 2/2 pituitaries is most probably responsibleThe uterine hyperplasia appeared as grossly enlarged
for the darkened dorsal coat color observed in agoutiand distended uterine horns studded with multiple, pol-
F2 mice (data not shown). b-endorphin content of theypoid cysts and occasionally associated with extensive
neurointermediate lobe was also increased in D21/2pelvic adhesions (Figures 6A and 6B). Some nodules
mice compared with both 1/1 and 2/2 mice (data notcontained a brownish fluid, but most were clear. Micro-
shown). Basal serum adrenocorticotrophic hormonescopic examination confirmed the presence of adeno-
(ACTH) levels were not significantly different betweenmyosis with endometrial stroma and glands extending
male sibling groups (30 6 39 pg/ml in D22/2 mice andbeyond the muscularis, forming prominent cysts (Figure
15 6 19 pg/ml in D21/1 mice), nor was adrenal weight6C). The endometrial elements exhibited no cytologic
(0.15 6 0.02 mg/g body weight in D22/2 mice and 0.14 6atypia, and reticulin stains confirmed the presence of
0.02 mg/g body weight in D21/1 mice), which is a highlyintact basement membrane around glandular struc-
reliable indicator of time integrated serum ACTH levelstures. There was no reactive hyperplasia, nor was there
destruction of myometrium. The ovaries were grossly (Orth et al., 1992).
Figure 6. Uterine Adenomyosis Is Common
in Aged D2 Receptor-Deficient Mice
(A) Uterus and ovaries of a D22/2 mouse with
moderate adenomyosis (lower) and a wild-
type control (upper). In the D22/2 mouse, the
smooth outer surface of the normal uterus is
marred by cystic protrusions in the adenomy-
otic uterus.
(B) A more severe presentation of adeno-
myosis in a D22/2 mouse(upper). The abdom-
inal fat has adhered to the uterine surface
(trimmed away in this photo), the entire sur-
face is obscured by polypoid cysts and nod-
ules, and the uterine horns appear shorter
and thicker than those of the control mouse
(lower). Scale bar, 1 cm.
(C) Histology of another severe case of aden-
omyosis in a D22/2 mouse. The uterus is
distorted by large cystic spaces (*) lined by
endometrial stroma and epithelium, but dis-
placed deep within the myometrium, charac-
teristic of adenomyosis. The arrow indicates
the serosal surface. Scale bar, 100 mm.
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Figure 7. Pituitary Intermediate Lobe Size Was Unchanged in D22/2 Mice
The B6 parental strain (A) typically has a smaller IL than either 129 or F2 hybrid mice. The IL of the wild-type parental strain 129/SvEv (B) is
more prominent than in an F2 D22/2 mouse (C). Abbreviations: NL, neural lobe; IL, intermediate lobe; AL, anterior lobe. Scale bar, 100 mm.
Discussion 1972), estrogen administration (Scheithauer et al., 1989),
drugs (Horvath, 1988), or, rarely, of the idiopathic type
(Jay et al., 1991; Peillon etal., 1991). A similar pathophys-D2 Dopamine Receptor-Deficiency
iological presentation was reported previously for theand Hyperprolactinemia
lactotroph hyperplasia associated with the ectopic ex-The absence of dopaminergic tone, normally provided
pression of nerve growth factor in the pituitary ofby the inhibitory action of D2 receptors, resulted in the
transgenic mice (Borrelli et al., 1992). Furthermore, theupregulated secretion of prolactin from anterior lobe
pituitary glands of the D2 receptor-deficient micelactotrophs in both male and female D22/2 mice. Despite
showed no signs of neoplastic transformation. Otherthe lack of D2 receptors, the normal sexual dimorphism
transgenic mouse models with pituitary cell-specific ex-in prolactin secretion was maintained in mutant mice,
pression of GH releasing hormone (Asa et al., 1990,indicating the important independent role of sex steroid
1992) or transforming growth factor-a (McAndrew ethormones on prolactin synthesis. The promotion of pro-
al., 1995) have resulted in adenomas characterized bylactin transcription and storage by estrogen assures that
disruption of the acinar architecture, absence of reticulinfemale mice have adequate prolactin reserves to re-
fibers, the presence of binucleate cells, and focal con-spond to the physiologic demands of pregnancy or lac-
centrations of a single adenohypophysial cell type. Thetation. The much greater increase in serum prolactin
absence of these primary indicators of transformationlevels of young adult wild-type female mice in response
in pituitary glands of the D22/2 mice points to a directto the acute blockade of D2 dopamine receptors by
haloperidol, compared with the baseline prolactin levels stimulation of normal lactotrophs, resulting in diffuse
of chronically D2 receptor-deficient mice, can be ex- proliferation, as opposed to transformation of one or a
plained by the constitutively stimulated secretory state few lactotrophs followed by unregulated clonal growth
of the lactotrophs in D22/2 mice. Haloperidol, at a high and tumor development.
dose, was completely without effect on serum prolactin The peliosis seen in the hyperplastic anterior pituitar-
levels in the D22/2 mice, indicating that none of the ies is a rare human disorder of unknown etiology. In
other known dopamine receptors are important for the the D2 receptor-deficient mice, the exact cause of the
dopaminergic control of lactotrophs. Although D21/2 extravasation of red blood cells is not known but may
mice have only 50% of the D2 receptor number of 1/1 be attributed to the hormonal dysregulation evidenced
mice, they maintain a normal secretory response tohalo- in the surrounding cells. Hormonal dysregulation has
peridol, probably because the pituitary has a large D2 been suggested as a pathogenic factor in cases of pel-
receptor ªreserveº (Meller et al., 1991). iosis of islets of Langerhans or in pancreatic endocrine
tumors, as it has in the more common peliosis of liver
or spleen (Kovacs et al., 1986).Pathogenesis of Lactotroph Hyperplasia
Is Multifactorial D2 receptor activation has been shown to be antimito-
genic in several models. Bromocriptine treatment re-The lactotroph hyperplasia observed in middle-aged
D22/2 female mice is similar, histologically, to that seen duces the size of prolactin secreting macroadenomas
in 50%±80% of cases (Wass et al., 1982) and decreasesin patients with prolactin cell hyperplasia due to preg-
nancy (Asa et al., 1982; Scheithauer et al., 1990), disrup- DNA synthesis and cell growth (Melmed et al., 1986).
Because D2 receptor activation inhibits adenylyl cyclasetion of the hypophysial stalk or hypothalamic destruc-
tion (Horvath, 1988), liver failure (Jung and Russfield, and consequently cAMP levels, we measured the cAMP
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content of the anterior lobes from D22/2 mice to deter- that tyrosine-phosphorylated JAK levels were increased
in the hyperplastic pituitaries, we performed a Westernmine if there was a positive correlation among the lack
of D2 receptors, elevated cAMP levels, and increased blot analysis of total cell lysates from 1-year-old and
2-month-old D22/2 mice (data not shown). Although apituitary growth. Contrary to our expectations, cAMP
content was actually decreased in theD22/2 female mice 130 kDa band was clearly detected with an anti-JAK
antibody, we were unable to detect the same phosphor-compared with D21/1 mice. Therefore, it is unlikely that
the hyperplastic response in the mice can be explained ylated band with a monoclonal anti-phosphotyrosine
antibody and a [125I]-labeled second antibody inany pitu-by a mechanism directly involving cAMP and protein
kinase A. Tyrosine phosphorylation is another key regu- itary sample. Therefore, this standard assay for acutely
stimulated cell lines was not sufficiently sensitive tolator of the cell cycle. In transfected GH4ZR7 cells, sig-
naling mediated by the D2 dopamine receptor inhibits definitivelydemonstrate activation of the major prolactin
receptor signaling pathway in whole anterior pituitaries.DNA synthesis and activates a phosphotyrosine phos-
phatase activity, among othereffects (Florio et al., 1992). Additional autocrine or paracrine positive feedback
mechanisms are accomodated by this model of lacto-The converse situation of decreased phosphotyrosine
phosphatase activity in D2 receptor-deficient lacto- troph hyperplasia. For example, transforming growth
factor-a is produced by lactotrophs; its receptor, whichtrophs could contribute to the observed mitogenesis by
shifting the balance of phosphorylated and nonphos- has tyrosine kinase activity, is also present on lacto-
trophs; and this growth factor has been shown pre-phorylated forms of key intracellular cell cycle regu-
lators. viously to have a mitogenic effect on lactotroph cells
(McAndrew et al., 1995). Further evidence to test theseComplete lack of D2-mediated dopaminergic tone
may be the initiating event that leads to lactotroph hy- hypotheses of paracrine positive feedback loops might
be obtained by intercrossing the D2 dopamine and pro-perplasia, but it is apparently insufficient, by itself, to
explain the phenotype. Only female mice developed hy- lactin receptor-deficient mice (Ormandy et al., 1997).
perplastic anterior pituitaries, suggesting a critical role
for sex steroid hormones. In previous studies, chronic Pathogenesis of Uterine Adenomyosis
estrogen treatment has been shown to induce prolacti- A large proportion of the female D22/2 mice developed
nomas in susceptible strains of rats (Phelps and Hymer, uterine adenomyosis, most commonly in mice greater
1983), and estrogen promotes the transcription of the than one year of age. Although the etiology of adeno-
prolactin gene (Steinmetz et al., 1997). However, D22/2 myosis is unknown, in previous animal models, it has
mice did not have elevated estradiol levels. It is possible been associated with hyperprolactinemia produced by
that estrogen receptors are upregulated in lactotrophs the dopamine receptor antagonists perphenazine, met-
of D22/2 female mice, resulting in an increased cellular oclopramide, or sulpiride (Singtripop et al., 1991), by
response to normal estradiol levels. The high testoster- ectopic pituitary grafts that isolate the pituitary from
one/estradiol ratio in male mice is known to downregu- inhibitory dopamine input (Husby et al., 1985), or by
late estrogen receptors, possibly preventing the devel- prenatal exposure to diethylstilbesterol (Husby and
opment of hyperplasia in males, despite serum estradiol Thurlow, 1982). In these previous models, the adeno-
levels identical to those of females and the identical myosis appeared to be estrogen-dependent, since it
loss of D2 receptors. Even though melanotrophs can waned in aged animals with declining ovarian function.
respond with growth changes to pharmacologic treat- The uterine myometrium and endometrium are both
ment with dopamine receptor ligands in the time frame sites of abundant prolactin receptors (Ben-Jonathan et
of 1±2 weeks (Hollt et al., 1982; Chronwall et al., 1987, al., 1996). Recently, it was demonstrated that prolactin
1988), the fact that the IL of the D22/2 mice did not is necessary for blastocyst implantation and embryonic
become hyperplastic over a period of up to one year development (Ormandy et al., 1997). A parsimonious
also indicates that additional intracellular mechanisms explanation for the hyperplastic disorders in both the
are required to perpetuate the lactotroph hyperplasia. uterus and pituitary of D2 receptor-deficient mice, and
Another candidate that can explain the delayed devel- their protracted time course, is a common mitogenic
opment of lactotroph hyperplasia in only female D22/2 stimulation from the progressive hyperprolactinemia.
mice is prolactin itself. The expression of prolactin re-
ceptors on anterior pituitary lactotrophs (Doppler, 1994;
Genetic Background and PituitaryMorel et al., 1994; Ben-Jonathan et al., 1996) could allow
Intermediate Lobe Sizean autocrine feed-forward loop to become established.
We found a dramatic difference in the size of the pituitaryMale D22/2 mice, whose prolactin levels arenot substan-
IL between wild-type 129/SvEv and C57BL/6J mice. Thetially higher than wild-type females, may never achieve
genetic basis of this difference is unknown, but it is ofthe elevated prolactin ªthresholdº necessary to estab-
interest that gene knockout mice created on the 129 3lish the self-perpetuating hyperplastic lesion. Signal
B6 hybrid genetic background, with disruptions of eithertransduction of the prolactin receptor occurs primarily
the retinoblastoma tumor suppressor gene (Hu et al.,through JAK2, a tyrosine kinase family member whose
1994; Williams et al., 1994) or the p27(Kip1) gene, (Feromajor phosphorylation targets are the STAT 1 and STAT
et al., 1996) have a propensity to develop tumors of the5 proteins (Doppler, 1994; Da Silva et al., 1994; Liu et
IL. Despite the high growth potential of the normal 129al., 1997). Phosphorylated STAT transcription factors
IL and the known acute and subchronic effects of dopa-are translocated to the nucleus and are involved in cell
mine antagonists to increase the number of melanotrophcycle regulation and mitogenesis of prolactin-respon-
sive cells (Liu et al., 1997). To address the possibility cells (Chronwall et al., 1988), D2 receptor-deficient mice
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evaluation if any gross abnormalities were observed. Samples usednever developed enlargement of the IL outside of the
for light microscopy were fixed in buffered formalin and embeddedrange seen in D2 receptor 1/1 F2 hybrids. Elimination
in paraffin; sections4±5 mm thick werethen stained with hematoxylinof the vast majority of 129 alleles, by five backcrosses
and eosin or with the Gordon-Sweet silver method to demonstrate
of the D2 receptor mutation onto the congenic B6 back- the reticulin fiber network. Intermediate lobe thickness was mea-
ground, still failed to reveal an independent effect of the sured using a Leitz microscope with a Mertz square-basedmicrome-
ter. Sections of glands were all in the horizontal plane and werechronic absence of D2 receptors on IL size. Therefore,
examined by an independent observer, blinded to the tissue identifi-unlike the anterior lobe lactotrophs, which increase pro-
cation. At least 10 measurements per gland were obtained, andgressively in number, melanotroph growth must be
results were expressed as thickness in mm 6 SEM.checked by other mechanisms in the D22/2 mice. One
Immunocytochemical stains to localize adenohypophysial hor-
possible mechanism is the expression of other D2-like mones were performed using the streptavidin-biotin-peroxidase
dopamine receptors in these cells. In support of this technique. Primary antisera directed against rat pituitary hormones
were used at the specified dilutions: GH, 1:2500; prolactin (PRL),idea, we have demonstrated D4 receptor mRNA by re-
1:2500; b-thyrotropin releasing hormone (b-TSH), 1:3000; b-FSH,verse-transcription PCR in a mouse melanotroph cell
1:600; b-LH, 1:2500 (National Hormone andPituitary Program, Rock-line generated in our laboratory (unpublished data).
ville, MD); and ACTH prediluted preparation further diluted 1:20Loss of the D2 receptor did affect the regulation of
(Dako Corporation, Carpinteria, CA). Pituitary tissue for immunofluo-
POMC peptide storage in the IL, despite a lack of effect rescence was prepared from mice after cardiac perfusion with neu-
on melanotroph growth. D22/2 mice had decreased IL tral buffered 4% paraformaldehyde. Free- floating, 20 mm cryostat
sections were labeled with anti-PRL S9 at a dilution of 1:25 (Nationalcontent of a-MSH, probably reflecting the constitutive
Hormone and Pituitary Program), followed by FITC-conjugated goatrelease of POMC peptides produced by the release of
anti-rabbit IgG at a dilution of 1:200 and Hoechst dye no. 33528 (1dopaminergic inhibition. In contrast, D21/2 mice actually
mg/ml). Optical sections were then examined on a Leica confocalhad significantly increased IL content of a-MSH. The
microscope.
increased storage might reflect a proportionately Tissues examined by transmission electron microscopy were
greater effect of loss of half of the D2 receptors on fixed in 2.5% glutaraldehyde, postfixed in 1% osmium tetroxide,
dehydrated in graded ethanols and propylene oxide, and then em-synthesis of POMC versus release from secretory gran-
bedded in Spurr's epoxy-resin. Semi-thin sections werestained withules. Serum ACTH and adrenal gland weight were unaf-
toluidine blue; ultra-thin sections of selected areas were stainedfected in the D22/2 mice, consistent with the known
with uranyl acetate and lead citrate and examined with a Phillipsexpression of D2 receptors on IL melanotrophs but not
CM 100 Biotwin electron microscope.
AL corticotrophs.
Serum Sampling and Biochemical MeasurementsConclusion
Two-site immunoradiometric assays of serum ACTH (Nichols Insti-
In these studies, we have documented ways in which tute Diagnostics) were performed on samples taken from stress-
the D2 receptor mediates the proliferative events of two free animals killed by decapitation. Basal serum prolactin levels
tissues, the pituitary and the uterus, by disruption of a were also taken from the same nonstressed, randomly housed (not
grouped by genotype) mice and determined by radioimmunoassaycomplex endocrine homeostasis. We propose that the
using a specific mouse prolactin antisera (National Hormone andpathogenesis of hyperplasia involves a combination of
Pituitary Program, Rockville, MD). The acute prolactin secretoryseveral factors including the direct loss of D2 receptor
response to haloperidol was assessed both within subject as well
signaling, a permissive estradiol/testosterone milieu, as between genotypes using the following experimental design:
and an autocrine or paracrine positive feedback loop T 5 0, intraperitoneal injection of 10 ml/kg of 0.9% saline; T 5 1 hr,
involving secreted products of the target tissues, includ- tail bleed for a predrug sample, followed by intraperitoneal injection
of 5 mg/kg (10 ml/kg) haloperidol; T 5 2 hr, sacrifice by decapitationing prolactin itself. The anterior pituitary hyperplasia
and collection of postdrug serum sample.demonstrated in the D2 receptor-deficient mice pro-
Pituitaries were harvested from stress-free animals, and the neu-vides a new animal model for determining the potential
rointermediate lobes were separated from the anterior lobes. The
effects on female patients undergoing long-term therapy
a-MSH and b-endorphin contents of the neurointermediate lobes
with D2 dopamine antagonists,and for testing new treat- were determined by radioimmunoassay as described previously
ments for D2 agonist-resistant hyperprolactinemia. (Low et al., 1993), while the total cAMP content of the anterior lobes
was determined by competetive displacement of [3H]-cAMP from a
high affinity cAMP binding protein using a commercial kit (DuPont).Experimental Procedures
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